Zydus receives USFDA tentative approval for Lorcaserin Hydrochloride Tablet
Capital MarketZydus Cadila has received the tentative approval from the USFDA to market Lorcaserin Hydrochloride Tablets (US RLD Belviq Tablets), 10 mg. The drug is used together with diet and exercise to treat obesity. It will be manufactured at the group's formulations manufacturing
facility at SEZ.
The group now has 278 approvals and has so far filed over 330 ANDAS since the commencement of the filing process in FY 2003-04.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
